gefitinib treatment survival prognostic clinical prognosis therapy
gefitinib treatment survival prognostic clinical prognosis
gefitinib treatment survival prognostic clinical therapy
gefitinib treatment survival prognostic prognosis therapy
gefitinib treatment survival clinical prognosis therapy
gefitinib treatment prognostic clinical prognosis therapy
gefitinib survival prognostic clinical prognosis therapy
treatment survival prognostic clinical prognosis therapy
gefitinib treatment survival prognostic clinical prognosis therapy outcome
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level overall
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level overall patients
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level overall patients PFS
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level overall patients PFS relapse-free
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level overall patients PFS relapse-free response
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level overall patients PFS relapse-free response review
gefitinib treatment survival prognostic clinical prognosis therapy outcome kinase resistance Gleason targets advance associate benefit ci disease drugs effect factor OS grading median month oral receive recurrence recurrence-free trastuzumab trial year capecitabine associated base cholangiocarcinoma develop disease-free existing female phase I phase II inhibitor level overall patients PFS relapse-free response review therapeutical